Pursuant to Regulation 29 of SEBI (LODR) Regulations, 2015, Denis Chem Lab has informed that the next Meeting of the Board of Directors of the Company is scheduled to be held on Friday, the 30th May, 2025 to transact the following: 1. to consider, approve and take on record the Audited Standalone Financial Results of the Company for the financial year 2024-25 ended on 31st March, 2025; 2. to recommend a final dividend, if any, on the equity shares of the Company for the financial year 2024-25 ended on 31st March, 2025. Further that as intimated to the Exchange vide Letter dated 21st March, 2025, the Trading Window of the Company shall continue to remain closed for designated persons till 48 hours after the declaration of Audited Financial Results for the quarter and year ended on 31st March, 2025 in terms of Company’s Code of Conduct for prevention of Insider Trading and SEBI (Prohibition of Insider Trading) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: